Provided by Tiger Fintech (Singapore) Pte. Ltd.

Mural Oncology

3.90
+0.24006.56%
Post-market: 3.85-0.0500-1.28%19:59 EDT
Volume:110.82K
Turnover:418.16K
Market Cap:66.61M
PE:-0.43
High:3.94
Open:3.70
Low:3.64
Close:3.66
Loading ...

Company Profile

Company Name:
Mural Oncology
Exchange:
NASDAQ
Establishment Date:
2017
Employees:
109
Office Location:
10 Earlsfort Terrace,Dublin,Ireland
Zip Code:
D02 T380
Fax:
- -
Introduction:
Mural Oncology Plc, a clinical-stage oncology company, focuses on discovering and developing immunotherapies for the treatment of patients with cancer. The company's lead product candidate includes nemvaleukin alfa for the treatment of mucosal melanoma as a monotherapy and platinum-resistant ovarian cancer in combination with pembrolizumab. It also develops engineered interleukin-18 and tumor-targeted interleukin-12 programs. The company was incorporated in 2017 and is based in Dublin, Ireland. As of November 15, 2023, Mural Oncology Plc operates as a former subsidiary of Alkermes plc.

Directors

Name
Position
Benjamin Hickey
Director
Francis Cuss
Director
Scott Jackson
Director
Susan Altschuller
Director

Shareholders

Name
Position
Caroline Loew
Chief Executive Officer
Maiken Keson Brookes
Chief Legal Officer